MedTrace Logo

Sequential Administration of Oral 6-Thioguanine (6-TG) After Methotrexate (MTX) in Patients With Relapsed Hodgkin's Disease (Phase II)

NCT00587873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2009-06-12

No results posted yet for this study

Summary

The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with recurrent or resistant Hodgkin's disease (HD) treated with sequential administration of oral 6-Thioguanin (6-TG) after IV Methotrexate (MTX).

Conditions

  • Hodgkin's Disease

Interventions

DRUG

Methotrexate

MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion

DRUG

Leucovorin calcium

5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.

DRUG

6-Thioguanine

6-TG 300 mg/m2 PO as a single oral dose

Sponsors & Collaborators

Principal Investigators

  • Tanya Trippett, MD · Memorial Sloan-Kettering Cancer Center/94-030

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-03-31
Primary Completion
2003-12-31
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00587873 on ClinicalTrials.gov